Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.73 +3.01%

+$0.81 today

Market cap
$1.81B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 5.16M

Average 1.81M

RARE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Ultragenyx Pharmaceutical Inc.NASDAQ: RARE

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $30M fell 24.8% year over year, behind the -11.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 19.5% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.

Context

  • Stock-based compensation amounted to 22.7% of revenue in FY2025, down 5.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -24.8% toward the trailing-twelve-month pace of -11.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$30M-19.5% QoQ
Last fiscal yearDec 2025
$153M-3.2% YoY
LTMMar 2026
$142.83M-11.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.8%——
1 year-3.2%——
3-year CAGR+5.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
153M USD
Year-over-year change
-3.2%
4-year CAGR
+9.9%

Stock-Based Compensation vs competitors

How RARE compares with its peers on the latest reported figures

  • RARE's LTM Mar 2026 stock-based compensation of $142.83M is the 2nd largest of the 11 companies compared; the peer median is $34.93M.
  • Its year-over-year change of -11.3% is the 9th highest of 11, against a peer median of -6.4%.
  • Stock-based compensation amounts to 21.3% of revenue for RARE, versus a peer median of 39.4%.
RARE Competitors Peer median
Stock-Based Compensation for RARE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$172.73B +92559.3%-2.6%16.8%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$142.83M -11.3%+5.5%21.3%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$111.95M -7.0%+13.3%15.7%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$84.66M +15.0%-12.3%8.4%
MGTXMeiraGTx Holdings plcLTM Mar 2026$47.93M +107.3%-8.3%60.1%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$35.22M -20.0%+6.1%—
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M -7.4%-5.4%39.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$19.48M -28.2%+8.7%22.1%
QUREuniQure N.V.LTM Mar 2026$18.36M -5.7%-19.7%101.5%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$8.33M +7.1%+52.3%57.3%
MREOMereo BioPharma Group plcLTM Mar 2026$6.93M -9.1%+16.8%1385.0%
Peer median (excluding RARE) $34.93M-6.4%+1.8%39.4%

Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(454.03M)(707.42M)(606.64M)(569.18M)(575M)
Depreciation & Amortization13.24M18.22M26.01M35.54M35M
Deferred Income Tax48.67M0(1.62M)00
Stock-Based Compensation104.95M130.38M135.21M158.03M153M
Change in Working Capital(63.24M)60.24M(15.1M)13.92M(23M)
Accounts Receivables(5.43M)(12.07M)(22.78M)(33.6M)(31M)
Inventory(3.12M)(9.7M)(6.93M)(11.21M)(6M)
Accounts Payables2.81M79.85M2.38M46.99M24M
Other Working Capital(57.49M)2.16M12.23M11.73M(10M)
Other Non-Cash Items11.71M118.12M(12.67M)(52.5M)(56M)
Operating Cash Flow(338.7M)(380.47M)(474.81M)(414.19M)(466M)
Capital Expenditures(73.09M)(146.12M)(46.77M)(7.49M)(6M)
Acquisitions (Net)0(75.03M)000
Purchases of Investments(1.01B)(614.74M)(526.38M)(408.61M)(186M)
Sales of Investments890.85M545.08M746.2M413.27M444M
Other Investing Activities(942K)(30.84M)(7.55M)(14.94M)(16M)
Investing Cash Flow(195.37M)(291.65M)168M(17.77M)236M
Debt Repayment0000392M
Common Stock Issued78.94M0379.76M380.98M86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities39.61M501.21M8.39M18.26M0
Financing Cash Flow118.55M501.21M388.14M399.24M478M
Effect of Forex Changes(1.19M)(1.08M)462K(2.53M)5.47M
Net Change in Cash(416.71M)(171.98M)81.8M(35.24M)253.47M
Free Cash Flow(411.79M)(526.59M)(521.57M)(421.68M)(472M)

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Intrinsic Alpha fair value

Locked

Current Price

$17.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.